Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

1.9%

1 terminated out of 52 trials

Success Rate

94.1%

+7.6% vs benchmark

Late-Stage Pipeline

21%

11 trials in Phase 3/4

Results Transparency

44%

7 of 16 completed with results

Key Signals

7 with results94% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (6)
Early P 1 (1)
P 1 (5)
P 2 (12)
P 3 (6)
P 4 (5)

Trial Status

Recruiting20
Completed16
Not Yet Recruiting9
Unknown3
Active Not Recruiting2
Withdrawn1

Trial Success Rate

94.1%

Benchmark: 86.6%

Based on 16 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT06855498Phase 3RecruitingPrimary

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT07213973Phase 2RecruitingPrimary

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07748169Recruiting

An Observational Study of Patients With Dermatologic Disease

NCT07384975Phase 2RecruitingPrimary

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

NCT07489573Phase 4RecruitingPrimary

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

NCT07263230Phase 2RecruitingPrimary

The Safety and Efficacy of Roflumilast Foam in HS

NCT07689188Phase 2Not Yet RecruitingPrimary

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT06993610Phase 2Active Not RecruitingPrimary

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT07668713Phase 1Not Yet RecruitingPrimary

FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study

NCT07659769RecruitingPrimary

Global Healthcare Study on Hidradenitis Suppurativa

NCT06241573Phase 2TerminatedPrimary

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT07287644Phase 2RecruitingPrimary

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT06993233Phase 2RecruitingPrimary

A Study With CIT-013 in HS Patients

NCT07316192Not ApplicableRecruitingPrimary

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

NCT07414550Not ApplicableRecruitingPrimary

Radiotherapy for Refractory Hidradenitis Suppurativa

NCT07554014Phase 4Not Yet RecruitingPrimary

A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa

NCT06960447Not ApplicableNot Yet RecruitingPrimary

Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

NCT07244510Phase 2RecruitingPrimary

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07123038Recruiting

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT06212999Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Scroll to load more

Research Network

Activity Timeline